nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC6A3—Gilles de la Tourette syndrome	0.814	1	CbGaD
Methamphetamine—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00767	0.112	CbGeAlD
Methamphetamine—MAOA—Clearance of dopamine—SLC6A3—Gilles de la Tourette syndrome	0.00767	0.0692	CbGpPWpGaD
Methamphetamine—SLC18A1—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00669	0.0604	CbGpPWpGaD
Methamphetamine—MAOA—Biogenic Amine Synthesis—HDC—Gilles de la Tourette syndrome	0.00608	0.0549	CbGpPWpGaD
Methamphetamine—SLC18A1—nervous system—Gilles de la Tourette syndrome	0.00498	0.0728	CbGeAlD
Methamphetamine—SLC18A1—central nervous system—Gilles de la Tourette syndrome	0.00479	0.0701	CbGeAlD
Methamphetamine—TAAR1—nervous system—Gilles de la Tourette syndrome	0.00468	0.0685	CbGeAlD
Methamphetamine—SLC18A1—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00464	0.0419	CbGpPWpGaD
Methamphetamine—TAAR1—central nervous system—Gilles de la Tourette syndrome	0.0045	0.0659	CbGeAlD
Methamphetamine—SLC18A1—brain—Gilles de la Tourette syndrome	0.0038	0.0557	CbGeAlD
Methamphetamine—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0035	0.0316	CbGpPWpGaD
Methamphetamine—TAAR1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00329	0.0297	CbGpPWpGaD
Methamphetamine—TAAR1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00319	0.0288	CbGpPWpGaD
Methamphetamine—TAAR1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00298	0.0269	CbGpPWpGaD
Methamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD3—Gilles de la Tourette syndrome	0.00274	0.0247	CbGpPWpGaD
Methamphetamine—SLC18A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00273	0.0247	CbGpPWpGaD
Methamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD4—Gilles de la Tourette syndrome	0.00266	0.024	CbGpPWpGaD
Methamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD2—Gilles de la Tourette syndrome	0.00248	0.0224	CbGpPWpGaD
Methamphetamine—TAAR1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00208	0.0188	CbGpPWpGaD
Methamphetamine—SLC18A2—midbrain—Gilles de la Tourette syndrome	0.00193	0.0283	CbGeAlD
Methamphetamine—SLC18A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00189	0.0171	CbGpPWpGaD
Methamphetamine—SLC18A2—Dopaminergic Neurogenesis—SLC6A3—Gilles de la Tourette syndrome	0.00189	0.0171	CbGpPWpGaD
Methamphetamine—MAOB—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.00189	0.017	CbGpPWpGaD
Methamphetamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00184	0.0166	CbGpPWpGaD
Methamphetamine—SLC18A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00181	0.0164	CbGpPWpGaD
Methamphetamine—SLC18A2—nervous system—Gilles de la Tourette syndrome	0.00159	0.0233	CbGeAlD
Methamphetamine—Diethylpropion—SLC6A3—Gilles de la Tourette syndrome	0.00154	0.216	CrCbGaD
Methamphetamine—SLC18A2—central nervous system—Gilles de la Tourette syndrome	0.00153	0.0224	CbGeAlD
Methamphetamine—SLC6A3—midbrain—Gilles de la Tourette syndrome	0.00146	0.0214	CbGeAlD
Methamphetamine—SLC6A4—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00141	0.0127	CbGpPWpGaD
Methamphetamine—SLC6A4—midbrain—Gilles de la Tourette syndrome	0.00134	0.0196	CbGeAlD
Methamphetamine—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00127	0.0115	CbGpPWpGaD
Methamphetamine—MAOB—midbrain—Gilles de la Tourette syndrome	0.00127	0.0186	CbGeAlD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00126	0.0114	CbGpPWpGaD
Methamphetamine—SLC18A2—brain—Gilles de la Tourette syndrome	0.00122	0.0178	CbGeAlD
Methamphetamine—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00121	0.0109	CbGpPWpGaD
Methamphetamine—SLC6A3—nervous system—Gilles de la Tourette syndrome	0.0012	0.0176	CbGeAlD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00118	0.0107	CbGpPWpGaD
Methamphetamine—Lisdexamfetamine—SLC6A3—Gilles de la Tourette syndrome	0.00117	0.163	CrCbGaD
Methamphetamine—SLC6A3—central nervous system—Gilles de la Tourette syndrome	0.00116	0.0169	CbGeAlD
Methamphetamine—SLC22A3—nervous system—Gilles de la Tourette syndrome	0.00113	0.0166	CbGeAlD
Methamphetamine—SLC6A4—nervous system—Gilles de la Tourette syndrome	0.0011	0.0161	CbGeAlD
Methamphetamine—SLC22A3—central nervous system—Gilles de la Tourette syndrome	0.00109	0.0159	CbGeAlD
Methamphetamine—MAOA—midbrain—Gilles de la Tourette syndrome	0.00109	0.0159	CbGeAlD
Methamphetamine—ADRA2B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00108	0.00973	CbGpPWpGaD
Methamphetamine—SLC6A4—central nervous system—Gilles de la Tourette syndrome	0.00106	0.0155	CbGeAlD
Methamphetamine—MAOB—nervous system—Gilles de la Tourette syndrome	0.00105	0.0153	CbGeAlD
Methamphetamine—ADRA2B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00105	0.00944	CbGpPWpGaD
Methamphetamine—ADRA2C—midbrain—Gilles de la Tourette syndrome	0.00105	0.0153	CbGeAlD
Methamphetamine—MAOB—central nervous system—Gilles de la Tourette syndrome	0.00101	0.0148	CbGeAlD
Methamphetamine—ADRA2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00101	0.00909	CbGpPWpGaD
Methamphetamine—SLC22A5—midbrain—Gilles de la Tourette syndrome	0.001	0.0147	CbGeAlD
Methamphetamine—ADRA2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000977	0.00882	CbGpPWpGaD
Methamphetamine—ADRA2B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000974	0.0088	CbGpPWpGaD
Methamphetamine—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.00097	0.0142	CbGeAlD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.000958	0.00865	CbGpPWpGaD
Methamphetamine—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.000934	0.0137	CbGeAlD
Methamphetamine—SLC6A3—brain—Gilles de la Tourette syndrome	0.000919	0.0134	CbGeAlD
Methamphetamine—ADRA2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00091	0.00822	CbGpPWpGaD
Methamphetamine—ADRA2B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000905	0.00818	CbGpPWpGaD
Methamphetamine—MAOA—nervous system—Gilles de la Tourette syndrome	0.000894	0.0131	CbGeAlD
Methamphetamine—ADRA2B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000879	0.00794	CbGpPWpGaD
Methamphetamine—SLC22A3—brain—Gilles de la Tourette syndrome	0.000865	0.0127	CbGeAlD
Methamphetamine—MAOA—central nervous system—Gilles de la Tourette syndrome	0.000861	0.0126	CbGeAlD
Methamphetamine—ADRA2C—nervous system—Gilles de la Tourette syndrome	0.00086	0.0126	CbGeAlD
Methamphetamine—ADRA2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000846	0.00764	CbGpPWpGaD
Methamphetamine—SLC6A4—brain—Gilles de la Tourette syndrome	0.000842	0.0123	CbGeAlD
Methamphetamine—ADRA2A—midbrain—Gilles de la Tourette syndrome	0.000834	0.0122	CbGeAlD
Methamphetamine—ADRA2C—central nervous system—Gilles de la Tourette syndrome	0.000828	0.0121	CbGeAlD
Methamphetamine—SLC18A1—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000825	0.00745	CbGpPWpGaD
Methamphetamine—ADRA2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000821	0.00741	CbGpPWpGaD
Methamphetamine—Phenylpropanolamine—SLC6A3—Gilles de la Tourette syndrome	0.000819	0.115	CrCbGaD
Methamphetamine—ADRA2B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000819	0.00739	CbGpPWpGaD
Methamphetamine—ADRA2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000817	0.00738	CbGpPWpGaD
Methamphetamine—MAOB—brain—Gilles de la Tourette syndrome	0.000801	0.0117	CbGeAlD
Methamphetamine—ADRA2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000793	0.00716	CbGpPWpGaD
Methamphetamine—ADRA2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000765	0.00691	CbGpPWpGaD
Methamphetamine—SLC6A2—brain—Gilles de la Tourette syndrome	0.000742	0.0109	CbGeAlD
Methamphetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000741	0.00669	CbGpPWpGaD
Methamphetamine—ADRA2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000739	0.00667	CbGpPWpGaD
Methamphetamine—Phentermine—SLC6A3—Gilles de la Tourette syndrome	0.00073	0.102	CrCbGaD
Methamphetamine—Dextroamphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000697	0.0975	CrCbGaD
Methamphetamine—Pseudoephedrine—SLC6A3—Gilles de la Tourette syndrome	0.000692	0.0969	CrCbGaD
Methamphetamine—ADRA2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.000687	0.0062	CbGpPWpGaD
Methamphetamine—ADRA2A—nervous system—Gilles de la Tourette syndrome	0.000686	0.01	CbGeAlD
Methamphetamine—MAOA—brain—Gilles de la Tourette syndrome	0.000683	0.01	CbGeAlD
Methamphetamine—ADRA2B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000682	0.00616	CbGpPWpGaD
Methamphetamine—ADRA2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000667	0.00602	CbGpPWpGaD
Methamphetamine—ADRA2A—central nervous system—Gilles de la Tourette syndrome	0.00066	0.00966	CbGeAlD
Methamphetamine—ADRA2C—brain—Gilles de la Tourette syndrome	0.000657	0.00961	CbGeAlD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000647	0.00585	CbGpPWpGaD
Methamphetamine—SLC22A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000641	0.00579	CbGpPWpGaD
Methamphetamine—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000639	0.00577	CbGpPWpGaD
Methamphetamine—ADRA2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000637	0.00576	CbGpPWpGaD
Methamphetamine—SLC22A5—brain—Gilles de la Tourette syndrome	0.000629	0.00921	CbGeAlD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000628	0.00567	CbGpPWpGaD
Methamphetamine—ADRA2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000621	0.00561	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000585	0.00529	CbGpPWpGaD
Methamphetamine—ADRA2B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000574	0.00518	CbGpPWpGaD
Methamphetamine—Amphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000561	0.0786	CrCbGaD
Methamphetamine—ADRA2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000536	0.00484	CbGpPWpGaD
Methamphetamine—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.000531	0.00777	CbGeAlD
Methamphetamine—ADRA2A—brain—Gilles de la Tourette syndrome	0.000524	0.00767	CbGeAlD
Methamphetamine—ADRA2A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000518	0.00467	CbGpPWpGaD
Methamphetamine—Benzphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000516	0.0723	CrCbGaD
Methamphetamine—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.000511	0.00748	CbGeAlD
Methamphetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.000499	0.0045	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000493	0.00445	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000478	0.00432	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000446	0.00403	CbGpPWpGaD
Methamphetamine—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000435	0.00393	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000419	0.00378	CbGpPWpGaD
Methamphetamine—SLC6A4—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000418	0.00377	CbGpPWpGaD
Methamphetamine—Amphetamine—DRD2—Gilles de la Tourette syndrome	0.000418	0.0585	CrCbGaD
Methamphetamine—SLC18A2—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000415	0.00375	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00041	0.0037	CbGpPWpGaD
Methamphetamine—CYP2D6—brain—Gilles de la Tourette syndrome	0.000406	0.00594	CbGeAlD
Methamphetamine—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000359	0.00325	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000352	0.00318	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000341	0.00308	CbGpPWpGaD
Methamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000337	0.00304	CbGpPWpGaD
Methamphetamine—SLC18A2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000318	0.00287	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000318	0.00287	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000312	0.00282	CbGpPWpGaD
Methamphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000291	0.00263	CbGpPWpGaD
Methamphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00029	0.00262	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000279	0.00252	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000273	0.00246	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00027	0.00244	CbGpPWpGaD
Methamphetamine—MAOA—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.000266	0.00241	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000253	0.00228	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000252	0.00227	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000246	0.00222	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—HDC—Gilles de la Tourette syndrome	0.000235	0.00213	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000229	0.00207	CbGpPWpGaD
Methamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000227	0.00205	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000224	0.00202	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.000224	0.00202	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000217	0.00196	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000209	0.00189	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000208	0.00188	CbGpPWpGaD
Methamphetamine—MAOA—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000204	0.00184	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000203	0.00183	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000203	0.00183	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000202	0.00182	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—HDC—Gilles de la Tourette syndrome	0.000199	0.0018	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000194	0.00175	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000189	0.00171	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000188	0.0017	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000188	0.0017	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000178	0.00161	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000176	0.00159	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000176	0.00159	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000173	0.00156	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000171	0.00154	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00017	0.00153	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000166	0.0015	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000165	0.00149	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000161	0.00146	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000161	0.00145	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00016	0.00145	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000158	0.00142	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000154	0.00139	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000153	0.00138	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00015	0.00136	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000149	0.00135	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000148	0.00134	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—HDC—Gilles de la Tourette syndrome	0.000148	0.00133	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000147	0.00133	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000145	0.00131	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000143	0.00129	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000136	0.00122	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000135	0.00122	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000135	0.00122	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000132	0.00119	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000132	0.00119	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000131	0.00118	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000127	0.00114	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000123	0.00111	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000123	0.00111	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000123	0.00111	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000122	0.0011	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—HDC—Gilles de la Tourette syndrome	0.000121	0.0011	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000115	0.00104	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000115	0.00103	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000113	0.00102	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000105	0.000952	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000103	0.000929	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	9.99e-05	0.000902	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	9.99e-05	0.000902	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	9.87e-05	0.000891	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.46e-05	0.000855	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	9.31e-05	0.00084	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	8.59e-05	0.000776	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	8.56e-05	0.000773	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	8.02e-05	0.000725	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	7.66e-05	0.000692	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	7.44e-05	0.000672	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	7.16e-05	0.000647	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	6.96e-05	0.000629	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	6.95e-05	0.000628	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	6.93e-05	0.000626	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	6.76e-05	0.00061	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	6.52e-05	0.000589	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	6.5e-05	0.000587	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	6.47e-05	0.000585	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	6.43e-05	0.000581	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	6.31e-05	0.00057	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	6.29e-05	0.000568	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.88e-05	0.000531	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	5.81e-05	0.000525	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	5.65e-05	0.00051	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.28e-05	0.000477	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	5.26e-05	0.000475	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.13e-05	0.000463	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.85e-05	0.000438	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.78e-05	0.000431	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.53e-05	0.00041	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.41e-05	0.000398	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.12e-05	0.000372	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.11e-05	0.000371	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.99e-05	0.00036	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.84e-05	0.000347	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.73e-05	0.000337	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.72e-05	0.000336	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	3.68e-05	0.000333	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.47e-05	0.000314	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.34e-05	0.000302	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.12e-05	0.000282	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.03e-05	0.000273	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.82e-05	0.000255	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.6e-05	0.000235	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.43e-05	0.00022	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.98e-05	0.000178	CbGpPWpGaD
